Healthy Bill

healthybill.net

Healthy Bill is the one stop shop for all your healthcare needs, providing access to inexpensive Diagnostic centers, Pharmacies, Hospitals and Wellness centers. Our mission is to make health care services accessible and affordable to everyone.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

news image

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

news image

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More

Industrial Impact

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

news image

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More

Cell and Gene Therapy

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

news image

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More
news image

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More
news image

AXIM® BIOTECHNOLOGIES COMPLETES PRE-CLINICAL DRUG STUDIES ON NEW COMPOUND PROVING TENFOLD GREATER INHIBITION OF TUMOR METASTASIS THAN PARENT COMPOUND

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

Read More
news image

Industrial Impact

GILEAD SCIENCES TO ACQUIRE MIROBIO

Gilead Sciences, Inc. | August 05, 2022

Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of imm...

Read More
news image

Cell and Gene Therapy

SPHERE FLUIDICS CLOSES A $40 MILLION FUNDING ROUND LED BY SOFINNOVA PARTNERS AND REDMILE GROUP

Sphere Fluidics | October 29, 2021

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million investment round. The round was led by Sofinnova Partner and Redmile Group investing on equal terms. Sphere Fluidics will use the funding to enable the expansion of the Company’s international sales activities in key markets and improving its support for customers. Furthermore...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us